Review article: trials on reflux disease -- the role of acid secretion and inhibition.
The importance of gastric acid in the pathophysiology of gastro-oesophageal reflux disease is substantiated by the extraordinary therapeutic success of acid inhibition in the management of the disease. The influence of many risk factors for gastro-oesophageal reflux disease is also mediated through their effect on gastric acid secretion and acid reflux. Helicobacter pylori reduces the risk of gastro-oesophageal reflux disease by causing corpus gastritis and reducing gastric acid output. The geographical and temporal trends of H. pylori infection in human populations and its influence on gastric acid secretion are responsible for much of the apparent epidemiology of gastro-oesophageal reflux disease. On average, intra-oesophageal exposure to acid is higher in patients who respond poorly to antisecretory medication. It also tends to increase with increasing severity of reflux disease. However, gastric acid secretion and intra-oesophageal acid exposure vary markedly in reflux patients. The degrees of gastric or intra-oesophageal acidity do not allow the prediction of the presence or severity of gastro-oesophageal reflux disease in the individual subject. The many clinical trials on gastro-oesophageal reflux disease indicate that the reflux of gastric acid constitutes an essential mechanism in the development of this disease, but that additional and partly unknown risk factors must contribute to its aetiology and promote its occurrence in the individual patient.